Transforming growth factor Β family members in regulation of vascular function: In the light of vascular conditional knockouts

Experimental Cell Research

Volumn 319, Issue 9, 2013, Pages 1264-1270

  Jakobsson, Lars ^a   van Meeteren, Laurens A ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF APPLIED SCIENCES UTRECHT   (Netherlands)

Author keywords

Angiogenesis; Conditional; Endothelial; TGF ; Vascular stability

Indexed keywords

ENDOGLIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 3;

ARTERIOVENOUS MALFORMATION; BLOOD VESSEL FUNCTION; ENDOTHELIUM CELL; EPISTAXIS; GENE DELETION; GENE INACTIVATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; RENDU OSLER WEBER DISEASE; REVIEW; SIGNAL TRANSDUCTION; TELANGIECTASIA; VASCULARIZATION;

EID: 84877110299     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2013.02.015     Document Type: Review

References (58)

1. Herbert S.P., Stainier D.Y. Molecular control of endothelial cell behaviour during blood vessel morphogenesis. Nat. Rev. Mol. Cell Biol. 2011, 12:551-564.
2. ten Dijke P., Arthur H.M. Extracellular control of TGFbeta signaling in vascular development and disease. Nat. Rev. Mol. Cell Biol. 2007, 8:857-869.
3. Cheifetz S., Bellón T., Calés C., Vera S., Bernabeu C., Massagué J., Letarte M. Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells. J. Biol. Chem. 1992, 267:19027-19030.
4. Wang X.-F., Lin H.Y., Ng-Eaton E., Downward J., Lodish H.F., Weinberg R.A. Expression cloning and characterization of the TGF-Β type III receptor. Cell 1991, 67:797-805.
5. Moustakas A., Heldin C.-H. The regulation of TGFbeta signal transduction. Development 2009, 136:3699-3714.
6. Moustakas A., Heldin C.-H. Non-Smad TGF-beta signals. J. Cell Sci. 2005, 118:3573-3584.
7. Oh S.P., Seki T., Goss K.A., Imamura T., Yi Y., Donahoe P.K., Li L., Miyazono K., ten Dijke P., Kim S., Li E. Activin receptor-like kinase 1 modulates transforming growth factor-beta 1 signaling in the regulation of angiogenesis. Proc. Natl. Acad. Sci. 2000, 97:2626-2631.
8. Goumans M.-J., Valdimarsdottir G., Itoh S., Rosendahl A., Sideras P., ten Dijke P. Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors. EMBO J. 2002, 21:1743-1753.
9. Ricard N., Ciais D., Levet S., Subileau M., Mallet C., Zimmers T.A., Lee S.-J., Bidart M., Feige J.-J., Bailly S. BMP9 and BMP10 are critical for postnatal retinal vascular remodeling. Blood 2012, 119:6162-6171.
10. Scharpfenecker M., van Dinther M., Liu Z., van Bezooijen R.L., Zhao Q., Pukac L., Löwik C.W.G.M., ten Dijke P. BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis. J. Cell Sci. 2007, 120:964-972.
11. Goumans M.-J., Valdimarsdottir G., Itoh S., Lebrin F., Larsson J., Mummery C., Karlsson S., ten Dijke P. Activin receptor-like kinase (ALK)1 is an antagonistic mediator of lateral TGFΒ/ALK5 signaling. Mol. Cell 2003, 12:817-828.
12. Lamouille S., Mallet C., Feige J.-J., Bailly S. Activin receptor-like kinase 1 is implicated in the maturation phase of angiogenesis. Blood 2002, 100:4495-4501.
13. David L., Mallet C., Mazerbourg S., Feige J.-J., Bailly S. Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells. Blood 2007, 109:1953-1961.
14. Mallet C., Vittet D., Feige J.-J., Bailly S. TGFbeta1 induces vasculogenesis and inhibits angiogenic sprouting in an embryonic stem cell differentiation model: respective contribution of ALK1 and ALK5. Stem Cells 2006, 24:2420-2427.
15. Lebrin F., Goumans M.-J., Jonker L., Carvalho R.L.C., Valdimarsdottir G., Thorikay M., Mummery C., Arthur H.M., ten Dijke P. Endoglin promotes endothelial cell proliferation and TGF-beta/ALK1 signal transduction. EMBO J. 2004, 23:4018-4028.
16. Blanco F.J., Santibanez J.F., Guerrero-Esteo M., Langa C., Vary C.P.H., Bernabeu C. Interaction and functional interplay between endoglin and ALK-1, two components of the endothelial transforming growth factor-beta receptor complex. J. Cell Physiol. 2005, 204:574-584.
17. Armulik A., Abramsson A., Betsholtz C. Endothelial/pericyte interactions. Circ. Res. 2005, 97:512-523.
18. Armulik A., Genové G., Betsholtz C. Pericytes: developmental, physiological, and pathological perspectives, problems, and promises. Dev. Cell 2011, 21:193-215.
19. Bobik A. Transforming growth factor-betas and vascular disorders. Arterioscler. Thromb. Vasc. Biol. 2006, 26:1712-1720.
20. Owens G.K. Regulation of differentiation of vascular smooth muscle cells. Physiol. Rev. 1995, 75:487-517.
21. Ding R., Darland D.C., Parmacek M.S., D'Amore P.A. Endothelial-mesenchymal interactions in vitro reveal molecular mechanisms of smooth muscle/pericyte differentiation. Stem Cells Dev. 2004, 13:509-520.
22. Dickson M.C., Martin J.S., Cousins F.M., Kulkarni A.B., Karlsson S., Akhurst R.J. Defective haematopoiesis and vasculogenesis in transforming growth factor-beta 1 knock out mice. Development 1995, 121:1845-1854.
23. Shull M.M., Ormsby I., Kier A.B., Pawlowski S., Diebold R.J., Yin M., Allen R., Sidman C., Proetzel G., Calvin D. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 1992, 359:693-699.
24. Carvalho R.L.C., Itoh F., Goumans M.-J., Lebrin F., Kato M., Takahashi S., Ema M., Itoh S., van Rooijen M., Bertolino P., Ten Dijke P., Mummery C.L. Compensatory signaling induced in the yolk sac vasculature by deletion of TGFbeta receptors in mice. J. Cell Sci. 2007, 120:4269-4277.
25. Sridurongrit S., Larsson J., Schwartz R., Ruiz-Lozano P., Kaartinen V. Signaling via the Tgf-beta type I receptor Alk5 in heart development. Dev. Biol. 2008, 322:208-218.
26. Park C., Lavine K., Mishina Y., Deng C.-X., Ornitz D.M., Choi K. Bone morphogenetic protein receptor 1A signaling is dispensable for hematopoietic development but essential for vessel and atrioventricular endocardial cushion formation. Development 2006, 133:3473-3484.
27. Upton P.D., Long L., Trembath R.C., Morrell N.W. Functional characterization of bone morphogenetic protein binding sites and Smad1/5 activation in human vascular cells. Mol. Pharmacol. 2008, 73:539-552.
28. Jiao K., Langworthy M., Batts L., Brown C.B., Moses H.L., Baldwin H.S. Tgfbeta signaling is required for atrioventricular cushion mesenchyme remodeling during in vivo cardiac development. Development 2006, 133:4585-4593.
29. Carvalho R.L.C., Jonker L., Goumans M.-J., Larsson J., Bouwman P., Karlsson S., Dijke P.T., Arthur H.M., Mummery C.L. Defective paracrine signaling by TGFbeta in yolk sac vasculature of endoglin mutant mice: a paradigm for hereditary haemorrhagic telangiectasia. Development 2004, 131:6237-6247.
30. Park S.O., Lee Y.J., Seki T., Hong K.-H., Fliess N., Jiang Z., Park A., Wu X., Kaartinen V., Roman B.L., Oh S.P. ALK5- and TGFBR2-independent role of ALK1 in the pathogenesis of hereditary hemorrhagic telangiectasia type 2. Blood 2008, 111:633-642.
31. S.O. Park, M. Wankhede, Y.J. Lee, E.-J. Choi, N. Fliess, S.-W. Choe, S.-H. Oh, G. Walter, M.K. Raizada, B.S. Sorg, S.P. Oh, Technical advance real-time imaging of de novo arteriovenous malformation in a mouse model of hereditary hemorrhagic telangiectasia, vol. 119, (2009).
32. Seki T., Hong K.-H., Oh S.P. Nonoverlapping expression patterns of ALK1 and ALK5 reveal distinct roles of each receptor in vascular development. Lab. Invest.: A J. Tech. Methods Pathol. 2006, 86:116-129.
33. Nguyen H.-L., Lee Y.J., Shin J., Lee E., Park S.O., McCarty J.H., Oh S.P. TGF-Β signaling in endothelial cells, but not neuroepithelial cells, is essential for cerebral vascular development. Lab. Invest.: A J. Tech. Methods Pathol. 2011, 91:1554-1563.
34. Hong K.-H., Lee Y.J., Lee E., Park S.O., Han C., Beppu H., Li E., Raizada M.K., Bloch K.D., Oh S.P. Genetic ablation of the BMPR2 gene in pulmonary endothelium is sufficient to predispose to pulmonary arterial hypertension. Circulation 2008, 118:722-730.
35. Jakobsson L., Franco C.A., Bentley K., Collins R.T., Ponsioen B., Aspalter I.M., Rosewell I., Busse M., Thurston G., Medvinsky A., Schulte-Merker S., Gerhardt H. Endothelial cells dynamically compete for the tip cell position during angiogenic sprouting. Nat. Cell Biol. 2010, 12:943-953.
36. Moya I.M., Umans L., Maas E., Pereira P.N.G., Beets K., Francis A., Sents W., Robertson E.J., Mummery C.L., Huylebroeck D., Zwijsen A. Stalk cell phenotype depends on integration of Notch and Smad1/5 signaling cascades. Dev. Cell 2012, 22:501-514.
37. Robson A., Allinson K.R., Anderson R.H., Henderson D.J., Arthur H.M. The TGFΒ type II receptor plays a critical role in the endothelial cells during cardiac development. Dev. Dyn.: An Off. Publ. Am. Assoc. Anat. 2010, 239:2435-2442.
38. Allinson K.R., Lee H.S., Fruttiger M., McCarty J., Arthur H.M. Endothelial expression of TGFΒ type II receptor is required to maintain vascular integrity during postnatal development of the central nervous system. PloS One 2012, 7:e39336.
39. Arnold T.D., Ferrero G.M., Qiu H., Phan I.T., Akhurst R.J., Huang E.J., Reichardt L.F. Defective retinal vascular endothelial cell development as a consequence of impaired integrin αVΒ8-mediated activation of transforming growth factor-Β. J. Neurosci.: Off. J. Soc. Neurosci. 2012, 32:1197-1206.
40. Itoh F., Itoh S., Adachi T., Ichikawa K., Matsumura Y., Takagi T., Festing M., Watanabe T., Weinstein M., Karlsson S., Kato M. Smad2/Smad3 in endothelium is indispensable for vascular stability via S1PR1 and N-cadherin expressions. Blood 2012, 119:5320-5328.
41. Gaengel K., Niaudet C., Hagikura K., Siemsen B.L., Muhl L., Hofmann J.J., Ebarasi L., Nyström S., Rymo S., Chen L.L., Pang M.-F., Jin Y., Raschperger E., Roswall P., Schulte D., Benedito R., Larsson J., Hellström M., Fuxe J., Uhlén P., Adams R., Jakobsson L., Majumdar A., Vestweber D., Uv A., Betsholtz C. The Sphingosine-1-Phosphate Receptor S1PR1 restricts sprouting angiogenesis by regulating the interplay between VE-cadherin and VEGFR2. Dev. Cell 2012, 23:587-599.
42. Rudini N., Felici A., Giampietro C., Lampugnani M., Corada M., Swirsding K., Garrè M., Liebner S., Letarte M., ten Dijke P., Dejana E. VE-cadherin is a critical endothelial regulator of TGF-beta signaling. EMBO J. 2008, 27:993-1004.
43. Frutkin A.D., Shi H., Otsuka G., Levéen P., Karlsson S., Dichek D.a. A critical developmental role for tgfbr2 in myogenic cell lineages is revealed in mice expressing SM22-Cre, not SMMHC-Cre. J. Mol. Cell Cardiol. 2006, 41:724-731.
44. Langlois D., Hneino M., Bouazza L., Parlakian A., Sasaki T., Bricca G., Li J.Y. Conditional inactivation of TGF-Β type II receptor in smooth muscle cells and epicardium causes lethal aortic and cardiac defects. Transgenic Res. 2010, 19:1069-1082.
45. Umans L., Cox L., Tjwa M., Bito V., Vermeire L., Laperre K., Sipido K., Moons L., Huylebroeck D., Zwijsen A. Inactivation of Smad5 in endothelial cells and smooth muscle cells demonstrates that Smad5 is required for cardiac homeostasis. Am. J. Pathol. 2007, 170:1460-1472.
46. El-Bizri N., Guignabert C., Wang L., Cheng A., Stankunas K., Chang C.-P., Mishina Y., Rabinovitch M. SM22alpha-targeted deletion of bone morphogenetic protein receptor 1A in mice impairs cardiac and vascular development, and influences organogenesis. Development 2008, 135:2981-2991.
47. Abdalla S.A., Letarte M. Hereditary haemorrhagic telangiectasia: current views on genetics and mechanisms of disease. J. Med. Genet. 2006, 43:97-110.
48. McAllister K.A., Grogg K.M., Johnson D.W., Gallione C.J., Baldwin M.A., Jackson C.E., Helmbold E.A., Markel D.S., McKinnon W.C., Murrell J. Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat. Genet. 1994, 8:345-351.
49. Johnson D.W., Berg J.N., Baldwin M.A., Gallione C.J., Marondel I., Yoon S.J., Stenzel T.T., Speer M., Pericak-Vance M.A., Diamond A., Guttmacher A.E., Jackson C.E., Attisano L., Kucherlapati R., Porteous M.E., Marchuk D.A. Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat. Genet. 1996, 13:189-195.
50. Gallione C.J., Richards J.A., Letteboer T.G.W., Rushlow D., Prigoda N.L., Leedom T.P., Ganguly A., Castells A., Ploos van Amstel J.K., Westermann C.J.J., Pyeritz R.E., Marchuk D.A. SMAD4 mutations found in unselected HHT patients. J. Med. Genet. 2006, 43:793-797.
51. Arthur H.M., Ure J., Smith A.J., Renforth G., Wilson D.I., Torsney E., Charlton R., Parums D.V., Jowett T., Marchuk D.A., Burn J., Diamond A.G. Endoglin, an ancillary TGFbeta receptor, is required for extraembryonic angiogenesis and plays a key role in heart development. Dev. Biol. 2000, 217:42-53.
52. Bourdeau A., Faughnan M.E., McDonald M.L., Paterson A.D., Wanless I.R., Letarte M. Potential role of modifier genes influencing transforming growth factor-beta1 levels in the development of vascular defects in endoglin heterozygous mice with hereditary hemorrhagic telangiectasia. Am. J. Pathol. 2001, 158:2011-2020.
53. Lebrin F., Srun S., Raymond K., Martin S., van den Brink S., Freitas C., Bréant C., Mathivet T., Larrivée B., Thomas J.-L., Arthur H.M., Westermann C.J.J., Disch F., Mager J.J., Snijder R.J., Eichmann A., Mummery C.L. Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia. Nat. Med. 2010, 16:420-428.
54. Dupuis-Girod S., Ginon I., Saurin J.C., Marion D., Guillot E., Decullier E., Roux A., Carette M.F., Gilbert-Dussardier B., Hatron P.Y., Lacombe P., Lorcerie B., Riviere S., Corre R., Giraud S., Bailly S., Paintaud G., Ternant D., Valette P.J., Plauchu H., Faure F. Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output. J. Am. Med. Assoc. 2012, 307:948-955.
55. Lindsay M.E., Schepers D., Bolar N.A., Doyle J.J., Gallo E., Fert-Bober J., Kempers M.J.E., Fishman E.K., Chen Y., Myers L., Bjeda D., Oswald G., Elias A.F., Levy H.P., Anderlid B.-M., Yang M.H., Bongers E.M.H.F., Timmermans J., Braverman A.C., Canham N., Mortier G.R., Brunner H.G., Byers P.H., Van Eyk J., Van Laer L., Dietz H.C., Loeys B.L. Loss-of-function mutations in TGFB2 cause a syndromic presentation of thoracic aortic aneurysm. Nat. Genet. 2012, 44:922-927.
56. Loeys B.L., Chen J., Neptune E.R., Judge D.P., Podowski M., Holm T., Meyers J., Leitch C.C., Katsanis N., Sharifi N., Xu F.L., Myers L.A., Spevak P.J., Cameron D.E., De Backer J., Hellemans J., Chen Y., Davis E.C., Webb C.L., Kress W., Coucke P., Rifkin D.B., De Paepe A.M., Dietz H.C. A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nat. Genet. 2005, 37:275-281.
57. Horbelt D., Guo G., Robinson P.N., Knaus P. Quantitative analysis of TGFBR2 mutations in Marfan-syndrome-related disorders suggests a correlation between phenotypic severity and Smad signaling activity. J. Cell Sci. 2010, 123:4340-4350.
58. Akhurst R.J., Hata A. Targeting the TGFbeta signaling pathway in disease. Nat. Rev. Drug Discovery 2012, 11:790-811.